Pfizer Inc. and BioNTech SE announced they have completed a submission to the FDA requesting Emergency Use Authorization (EUA) of a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.
Pfizer announced that the companies have submitted an application to the FDA for emergency use authorisation (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-microgram dose in the three-dose primary series for children 6 months through 4 years of age.
Celgene International S�rl,has announced that statistical significance was achieved for the primary endpoint of ACR 20 at week 16 for...
Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta (ofatumumab) had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta
Novartis confirmed plans for the 100% spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs (American Depositary Receipts) to commence on October 4, 2023
Pfizer Inc and BioNTech SE announced they have completed a submission to the FDA requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age
AstraZeneca announced positive top-line results of the Phase III, PINNACLE 4 trial in which Bevespi Aerosphere (glycopyrronium and formoterol fumarate...
Aerie Pharmaceuticals, Inc. reported the successful 90-day topline efficacy results of its Rocket 4 Phase III clinical trial of product...
Pfizer and BioNTech SE announced they have completed a submission to the FDA requesting Emergency Use Authorization (EUA) of a 10-micrograms booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age